Article
Audit Trail Architecture — What a Defensible System Looks Like
An audit trail that exists but is never reviewed is not a compliance control — it is a liability waiting to be discovered by an FDA investigator who…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
Audit Trail Architecture — What a Defensible System Looks Like
An audit trail that exists but is never reviewed is not a compliance control — it is a liability waiting to be discovered by an FDA investigator who…
Article
CMC Deficiency Letter Response Strategy: Turning FDA and EMA Questions Into Approval Accelerators
The average NDA CMC review cycle includes at least one round of deficiencies. The average ANDA review includes two. The companies that convert deficiency letters into expedited approvals…
Article
Annex 11 vs 21 CFR Part 11: Why US Compliance Does Not Equal EU Compliance
Most pharmaceutical companies operating in both the US and EU believe that if their electronic systems comply with 21 CFR Part 11, they also satisfy EU Annex 11…
Article
Module 2.3 Quality Overall Summary — Drug Product: The Summary That Frames Every Module 3 Drug Product Review Decision
"When a regulatory reviewer opens the QOS drug product section, they are looking for three things: that you understand why your formulation is designed the way it is,…
Article
ALCOA+ Data Completeness — The Deletion Problem FDA Finds First
FDA investigators are trained to look for what is missing from your data records before they look at what is present — and the deletion of failed runs,…
Article
Module 2.3 Quality Overall Summary — Drug Substance: Writing the Narrative FDA Reviewers Read Before Module 3
The Quality Overall Summary is the first CMC document a regulatory reviewer reads. It sets their expectations, frames the complexity of the submission, and either reassures them that…
Article
Catalent Indiana LLC FDA 483: 8 Observations at Bloomington, Indiana and the Aseptic/Sterile Manufacturing Pattern Every Sterile Injectable Quality Leader Should Assess
FDA investigators closed an 11-day inspection of Catalent Indiana LLC's sterile injectable facility in Bloomington, Indiana, on April 24, 2026, documenting eight inspectional observations spanning environmental monitoring, aseptic…
Article
3.2.P.8 Drug Product Stability: Building the Stability Program That Establishes a Defensible Shelf Life
"The proposed shelf life of 24 months is not supported by the data provided." Three years after ICH Q1E has been in effect, this deficiency continues to appear…
Article
ALCOA+ Attributability — Why Shared Logins Become Warning Letters
The shared laboratory login is one of the most common data integrity violations FDA finds during inspections — and it is also one of the most dangerous, because…
Article
3.2.P.7 Drug Product Container Closure System: Extractables, Leachables, and a Modern Risk-Based E&L Framework
Container-closure suitability and product-contact-material risk are long-standing CMC expectations. The current architecture should distinguish binding requirements and final guidance from evolving scientific frameworks: USP / provide extractables/leachables assessment…
Article
Wizcure Pharmaa Warning Letter: Data Integrity and the CMC Pattern Every Sterile OTC Drug Quality Director Must Recognize
On June 24, 2026, FDA issued Warning Letter 320-26-97 to Wizcure Pharmaa Private Limited in Bhiwadi, Rajasthan, India, following an inspection conducted December 3 to 10, 2025 —…
Article
Excelvision Warning Letter: Sterility Assurance Failure and the CMC Pattern Every Sterile Products Quality Director Must Recognize
On June 25, 2026, FDA issued Warning Letter 320-26-98 to Excelvision (a Fareva facility) in Annonay, France, following an inspection conducted January 12 to 22, 2026 — the…
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.